Peptides/LL-37

LL-37

research

Human antimicrobial peptide for immune defence, infection fighting, and wound healing

Cathelicidin
Type
SC injection
Route
Yes — vendors
Available in Thailand
Not typically
Clinic therapy

Availability in Thailand

LL-37 is available from Thai peptide vendors. It is not typically offered at mainstream clinics, though some clinics may include it in immune support protocols.

Prescription: Not required from vendors.

Legal status: Available as a research peptide in Thailand.

Where to Buy in Thailand

LL-37 pricing varies by vendor and vial size. Check vendor websites for current rates.

Vendors

Synergy Peptides

Bangkok

Premium GMP-certified peptides with verified COAs

View vendor →

Overview

LL-37 is the only human cathelicidin antimicrobial peptide — a first-line defence molecule produced by neutrophils, macrophages, and epithelial cells. It directly kills bacteria by disrupting their cell membranes, neutralises bacterial toxins, breaks apart biofilms (colonies of bacteria that resist antibiotics), and modulates the immune response. It represents the body's own innate antibiotic system.

How It Works

Direct antimicrobial action

LL-37 disrupts bacterial cell membranes through electrostatic interaction with negatively charged lipopolysaccharides (LPS), effectively punching holes in bacteria. It is effective against both gram-positive and gram-negative bacteria, as well as some fungi and enveloped viruses.

Biofilm disruption

One of LL-37's most valuable properties is its ability to break apart bacterial biofilms — the protective colonies that bacteria form to resist antibiotics. Biofilms are a major cause of chronic, treatment-resistant infections.

Immune modulation

Beyond direct killing, LL-37 modulates the immune response — recruiting immune cells to infection sites, enhancing adaptive immune responses, and reducing excessive pro-inflammatory cytokine release. This balanced approach prevents both under-response and harmful over-inflammation.

Wound healing promotion

LL-37 stimulates keratinocyte migration and proliferation and induces angiogenesis through VEGF upregulation, actively promoting wound healing alongside its antimicrobial effects.

Protocol Quick Reference

starting Dose
50-100 mcg/day
maintenance Dose
100-200 mcg/day or every other day
escalation
Start at 50 mcg, increase to 100-200 mcg based on tolerance and purpose
injection Sites
Subcutaneous — abdomen. For local infections, some practitioners inject near the affected area
full Titration
3-5 days at starting dose
cycle Length
2-6 weeks depending on purpose. For acute infections: shorter cycles. For chronic immune support: longer cycles with breaks
storage
Refrigerated 2-8°C after reconstitution. LL-37 can be sensitive to degradation — use within 2-3 weeks of reconstitution
reconstitution
Reconstitute with bacteriostatic water
timing
Any consistent time daily
special Notes
LL-37 is not a replacement for antibiotics in serious infections — it is a complementary immune support tool. Can be combined with thymosin alpha-1 for comprehensive immune enhancement. Handle with care as it is more fragile than many peptides.

Benefits & Uses

  • Broad-spectrum antimicrobial: Active against gram-positive and gram-negative bacteria, fungi, and enveloped viruses
  • Biofilm disruption: Breaks apart bacterial biofilms that resist traditional antibiotics — valuable for chronic infections
  • Immune enhancement: Recruits and activates immune cells while preventing harmful over-inflammation
  • Wound healing: Promotes wound healing through keratinocyte migration and angiogenesis
  • Endogenous molecule: Based on a peptide the human body naturally produces — not a foreign compound

Side Effects

Common

  • Injection site irritation
  • Mild redness or warmth at injection site

Less Common

  • Headache
  • Mild fatigue

Serious

  • Generally well-tolerated as an endogenous human peptide
  • May be pro-inflammatory at high doses — stay within recommended ranges
  • Not a substitute for medical treatment of serious infections
  • Long-term supplemental use data is limited

Related Peptides

FAQ

Can LL-37 replace antibiotics?

No — LL-37 is not a replacement for antibiotics in serious bacterial infections. It is a complementary immune support tool that can enhance the body's natural antimicrobial defence. Always seek proper medical treatment for infections.

What makes LL-37 unique among antimicrobial peptides?

LL-37 is the only human cathelicidin — it is the same molecule your own immune system produces. Its ability to disrupt bacterial biofilms is particularly valuable, as biofilms are a major cause of chronic infections that resist conventional antibiotics.

Can I use LL-37 for general immune support?

Yes — some practitioners recommend short cycles of LL-37 for general immune resilience, particularly during travel or seasonal illness periods. It can be combined with thymosin alpha-1 for comprehensive immune enhancement.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Peptides should be used under the guidance of a qualified healthcare professional. Individual results vary. Always consult your doctor before starting any peptide therapy.